A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Shandong Suncadia Medicine

Status and phase: Begins enrollment this month; Phase 1

Conditions: Moderate Pain in Knee Osteoarthritis; Severe Pain in Knee Osteoarthritis

Treatments: Drug: Celecoxib Capsule Placebo; Drug: HRS-2129 Tablet; Drug: HRS-2129 Tablet Placebo; Drug: Celecoxib capsule

Study type: Interventional

Funder types: Industry

Identifiers

NCT07351968

HRS-2129-106

Details and patient eligibility

About

Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Voluntarily sign the informed consent form before starting the activities related to the trial;
2. The Numerical Evaluation Scale (NRS) pain score of the index knee joint at screening is ≥ 4;
3. Subjects must be willing to discontinue all medical and non-medical treatments for osteoarthritis pain except rescue medication (acetaminophen) and not use prohibited analgesics throughout the study ;
4. Male and female subjects of childbearing potential must agree to use highly effective contraceptive measures with their partners from the signing of the informed consent form until 1 month after the last dose of investigational product.

Exclusion criteria

1. History of other diseases that may involve the target joint;
2. History of major trauma or surgery of knee joint and hip joint in the past year;
3. Plan to undergo surgical procedure during the study;
4. Most or complete loss of mobility;
5. There are other diseases that may confuse the assessment of osteoarthritis pain;
6. There is a neuropsychiatric disease, and the investigator's assessment may affect the evaluation of osteoarthritis (OA) or self-score;
7. There are serious or poorly controlled concomitant diseases;
8. Those who have a clear history of peptic ulcer, bleeding, perforation or obstruction within 1 year before screening, and have been clinically diagnosed;
9. Those who require drug treatment or surgical intervention;
10. History of malignant tumors within 5 years before screening;
11. Have a history of drug abuse, drug abuse and/or alcoholism within 2 years before screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 4 patient groups, including a placebo group

HRS-2129 High Dose Group

Experimental group

Description:

HRS-2129 high dose group.

Treatment:

Drug: HRS-2129 Tablet Placebo

Drug: HRS-2129 Tablet

Drug: Celecoxib Capsule Placebo

HRS-2129 Low Dose Group

Experimental group

Description:

HRS-2129 low dose group.

Treatment:

Drug: HRS-2129 Tablet Placebo

Drug: HRS-2129 Tablet

Drug: Celecoxib Capsule Placebo

Celecoxib Group

Active Comparator group

Description:

Celecoxib group.

Treatment:

Drug: Celecoxib capsule

Drug: HRS-2129 Tablet Placebo

Placebo Group

Placebo Comparator group

Description:

Placebo group.

Treatment:

Drug: HRS-2129 Tablet Placebo

Drug: Celecoxib Capsule Placebo